On Monday, SpringWorks Therapeutics stock saw its Relative Strength (RS) Rating improve to 86, marking a significant technical milestone. The company reported preliminary fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues of $61.5 million and $172.0 million, respectively. SpringWorks Therapeutics ended 2024 with approximately $462 million in cash, cash equivalents, and marketable securities.
SpringWorks Therapeutics also provided updates on its commercial portfolio and investigational pipeline during the 43rd Annual J.P. Morgan Healthcare Conference. The company's presentation included data from the pivotal Phase 2b ReNeu trial of mirdametinib, showing efficacy in treating neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The trial met its primary endpoint with confirmed objective response rates of 41% in adults and 52% in children.
Additionally, long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors demonstrated further reductions in tumor size, an increase in objective response rate (ORR), and sustained improvement in desmoid tumor symptoms. The company has also received FDA Priority Review for its New Drug Application (NDA) and validation of the EU Marketing Authorization Application for mirdametinib.
SpringWorks Therapeutics continues to participate in significant healthcare conferences, including the 7th Annual Evercore ISI HealthCONx Conference and the Jefferies London Healthcare Conference, to share updates and insights on its research and development efforts.
